Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.51 |
| ▸ | ITGAV | P06756 | 10/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868486 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6868159 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6868246 | 0.89 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6866389 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6868790 | 0.85 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL5567444 | 0.84 | ITGB3 (0.61) | ITGB3ITGAVITGA2BF2 | |
| SCHEMBL6861835 | 0.84 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6861761 | 0.82 | P2RX7 (0.45) | ITGB3ITGA2BP2RX7F2MMP1 | |
| SCHEMBL7216172 | 0.81 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7216180 | 0.81 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155003-B1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-6340679-B1 | FOR INHIBITING BONE RESORPTION, OSTEOPOROSIS, TUMOR GROWTH OR TUMOR METASTASIS, INFLAMMATION, OR FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS, RESTENOSIS, ARTERIOSCLEROSIS, NEPHROPATHIES, RETINOPATHIES OR RHEUMATOID ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-22 | — | — | US | disclosed |
| EP-1155003-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047564-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-17 | — | — | WO | disclosed |
| EP-1028114-A1 | Novel guanidine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2000-08-16 | — | — | EP | disclosed |